About PDL

PDL is a recognized leader in the discovery and development of humanized monoclonal antibodies for the treatment of disease. Our patented humanization technology platform is the most widely validated antibody technology in our industry. With seven marketed antibody products already licensed under our humanization patents and at least 40 additional humanized antibodies in clinical trials, PDL believes the promise of our humanization technology is well on the way to becoming fully realized.

Today, PDL is leveraging its expertise in antibody humanization to become a fully integrated biopharmaceutical company that creates, develops, manufactures and, in North America, markets proprietary biopharmaceutical products. PDL's most advanced clinical-stage program is visilizumab (Nuvion®) for the treatment of severe refractory ulcerative colitis. PDL also has antibodies in development for asthma and cancer. PDL believes these disease indications represent areas of significant unmet medical need.